Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reversible posterior leucoencephalopathy syndrome associated with sunitinib.

Literature DB >> 19382984

Reversible posterior leucoencephalopathy syndrome associated with sunitinib.

A Chen, N Agarwal.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Indoles
Pyrroles
Sunitinib

Year: 2009 PMID： 19382984 DOI： 10.1111/j.1445-5994.2009.01908.x

Source DB: PubMed Journal: Intern Med J ISSN： 1444-0903 Impact factor: 2.048

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors: Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal: Invest New Drugs Date: 2014-05-23 Impact factor: 3.850

Review 2. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors: Rashmi R Shah
Journal: Drug Saf Date: 2017-05 Impact factor: 5.606

3. Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.

Authors: Jaclyn Yoong; Geoffrey Chong; K Hamilton
Journal: Med Oncol Date: 2010-11-04 Impact factor: 3.064

Review 4. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.

Authors: Biswa M Padhy; Saravana P Shanmugam; Yogendra K Gupta; Aman Goyal
Journal: Br J Clin Pharmacol Date: 2011-05 Impact factor: 4.335

5. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.

Authors: Jamal Oulad Hadj; Rogier DEN Braven; Corrine Tillier; Hans M Schrijver; Henk M W Verheul; Hans J VAN DER Vliet
Journal: Oncol Lett Date: 2012-03-16 Impact factor: 2.967

Review 6. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors: Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal: Target Oncol Date: 2011-11-17 Impact factor: 4.493

7. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors: R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal: Gynecol Oncol Date: 2013-01-13 Impact factor: 5.482